Multiple endocrine neoplasia type 1 future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
==Reference== | ==Reference== | ||
{{Reflist}} | {{Reflist}} | ||
[[Category:Hereditary cancers]] |
Revision as of 15:14, 10 September 2015
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 future or investigational therapies On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 future or investigational therapies |
FDA on Multiple endocrine neoplasia type 1 future or investigational therapies |
CDC on Multiple endocrine neoplasia type 1 future or investigational therapies |
Multiple endocrine neoplasia type 1 future or investigational therapies in the news |
Blogs on Multiple endocrine neoplasia type 1 future or investigational therapies |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.
Future or Investigational Therapies
- Since MEN type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.[1]
- National and international collaborations are encouraged to recruit more patients with multiple endocrine neoplasia type 1 for clinical trials.
- Use of TRK inhibitors (tropomyosin receptor kinase inhibitors) for medullary thyroid cancer and pancreatic neuroendocrine tumors have been investigated under multicenter clinical trials.
- mTOR inhibitors for pancreatic neuroendocrine tumors are other trials undergoing investigation.
- Role of surgery for non functioning pancreatic neuroendocrine tumors are under investigation.
- The interaction between menin and mixed lineage leukemia protein 1(MLL1) also known as a histone H3 lysine 4 methyltransferase has been targeted to find cure for this disorder.
- Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for Multiple endocrine neoplasia type 1.
- Molecular phenotyping of tumors have been proposed to use to detect MEN type 1 tumors at an early stage.
Reference
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1210/jc.2012-1230 Check
|pmid=
value (help).